TP53 and non-small cell lung carcinoma: Moreover, newly discovered pharmacogenetic drivers, such as ROS1, RET, NTRK1‐3, BRAF, MET, TP53, and ERBB2, as well as the implementation of immunotherapy and early detection technologies, may further improve the 5‐year survival rate of NSCLC, not only PSC1.